Biotechnology - Anti-virals, Markets & Marketing

Filter

Popular Filters

Sanofi and PATH the first to bring large quantities of semisynthetic artemisinin antimalarial treatment to market

Sanofi and PATH the first to bring large quantities of semisynthetic artemisinin antimalarial treatment to market

12-08-2014

French drug major Sanofi and Seattle-based PATH have become the first to deliver large-scale batches…

Anti-viralsartemisininBiotechnologyMarkets & MarketingPATHSanofiUSA

BioAlliance’s Sitavig debuts in USA; new patent granted

BioAlliance’s Sitavig debuts in USA; new patent granted

22-07-2014

French drug developer BioAlliance Pharma says that its US partner Innocutis Holdings has launched Sitavig…

Anti-viralsBioAlliance PharmaBiotechnologyHealth Medical PharmaHerpesInnocutis HoldingsLabial herpesMarkets & MarketingMedicineMicrobiologyPatentsSitavigUSA

HIV market growth to be impacted by patent expiries

16-04-2014

Due to patent expirations of several key therapies, the human immunodeficiency virus (HIV) treatment…

Anti-viralsapricitabineAtriplaBiotechnologycensavudineelvucitabineGilead SciencesMarkets & MarketingPatentsResearchtenofovir alafenamideTruvadaViread

Mylan gets exclusive rights to distribute Gilead branded drugs in India

Mylan gets exclusive rights to distribute Gilead branded drugs in India

31-01-2014

US generics major Mylan says its India-based subsidiary has been named) exclusive branded medicines business…

AmbisomeAnti-viralsAsia-PacificBiotechnologyGilead SciencesIndiaMarkets & MarketingMylan LaboratoriesStribildTruvadaViread

US and European gastroenterologist's views on hepatitis C treatments

02-05-2013

Gastroenterologists in the USA and Europe by health care advisory firm Decision Resources agree that…

Anti-viralsBiotechnologyEuropeMarkets & MarketingNorth AmericaPharmaceuticalResearch

Mylan delivers "one pill once a day" ARV in South Africa; Cipla Debuts first Enbrel biosimilar

17-04-2013

USA-based generic drugmaker Mylan (Nasdaq: MYL) says that it has delivered, through its South African-based…

AmgenAnti-Arthritics/RheumaticsAnti-viralsAsia-PacificBiotechnologyCiplaEnbrelEtaceptGenericsMarkets & MarketingMylan LaboratoriesPfizerRest of the World

Roche teams up with Ascletis on hep C treatments for China

15-04-2013

Roche (ROG: SIX) has entered a collaboration with Ascletis Pharmaceuticals, a USA- and China-based biotech…

Anti-viralsAscletis PharmaceuticalsAsia-PacificBiotechnologydanoprevirLicensingMarkets & MarketingPharmaceuticalResearchRoche

Need for global policy innovation to tackle the "Silent Pandemic" that is hepatitis C, says EIU report

16-01-2013

There is an urgent need for countries around the world to develop strategies to tackle head-on the growing…

Anti-viralsBiotechnologyGlobalHealthcareMarkets & MarketingPharmaceutical

Sales of antiretroviral agents for HIV will decline slightly over next decade

18-12-2012

Major-market sales of antiretroviral (ARV) agents for HIV will decline slightly over the next decade,…

Anti-viralsBiotechnologydolutegravirGenericsGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRegulationViiV Healthcare

Gilead's Stribild to reinforce HIV/AIDS revenues as key patents expire

06-11-2012

US biotech firm Gilead Science's (Nasdaq: GILD) combination drug Stribild (elvitegravir 150mg/cobicistat…

Anti-viralsAtriplaBiotechnologyBristol-Myers SquibbGilead SciencesMarkets & MarketingPatentsReyatazStribildSustiva

Uptake of Peg-IFN agents for HCV in China and South Korea hindered by relatively high cost and their partial reimbursement status

21-10-2012

Although pegylated interferon (peg-IFN; Roche's Pegasys, Merck & Co's PegIntron) combined with ribavirin…

Anti-viralsAsia-PacificBiotechnologyIncivekMarkets & MarketingMerck & CoPegasysPegIntronPharmaceuticalRocheVictrelis

RusNano to start production of vaccines and organogels

09-01-2012

Russia’s RusNano (Russian Corporation of Nanotechnologies) has signed an agreement with Russian…

Anti-viralsBiotechnologyCardio-vascularEpidbiomedEuropeFinancialMarkets & MarketingMergers & AcquisitionsNanolekOncologyRusNanoVaccines

Back to top